Thomas von Briel

634 total citations
10 papers, 84 citations indexed

About

Thomas von Briel is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Thomas von Briel has authored 10 papers receiving a total of 84 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 4 papers in Surgery and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Thomas von Briel's work include Bone health and treatments (4 papers), Management of metastatic bone disease (3 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Thomas von Briel is often cited by papers focused on Bone health and treatments (4 papers), Management of metastatic bone disease (3 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Thomas von Briel collaborates with scholars based in Switzerland, Germany and Australia. Thomas von Briel's co-authors include Michael Payer, Serge Leyvraz, Paul Honegger, Cristiana Sessa, A Küpfer, T. Cerny, Alan V. Boddy, Janet Brunner, S.‐F. Hsu Schmitz and Michael Mark and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Thomas von Briel

10 papers receiving 80 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas von Briel Switzerland 6 49 47 17 13 11 10 84
Guanfu Cai China 7 58 1.2× 26 0.6× 45 2.6× 19 1.5× 14 1.3× 14 98
Audrey Rabeau France 6 64 1.3× 36 0.8× 10 0.6× 6 0.5× 18 1.6× 16 96
Fabiana Sousa Portugal 4 27 0.6× 35 0.7× 21 1.2× 9 0.7× 3 0.3× 10 60
F. Rivera Herrero Spain 5 62 1.3× 22 0.5× 18 1.1× 8 0.6× 14 1.3× 19 75
Sujata Rao United States 3 47 1.0× 20 0.4× 14 0.8× 15 1.2× 16 1.5× 8 84
Giuseppe Sena Italy 6 34 0.7× 16 0.3× 30 1.8× 14 1.1× 8 0.7× 12 74
Leona Koubková Czechia 7 102 2.1× 73 1.6× 7 0.4× 12 0.9× 18 1.6× 25 151
Marcin Ostrowski Poland 7 34 0.7× 74 1.6× 15 0.9× 3 0.2× 20 1.8× 14 121
Miriam Ahlborn Germany 4 57 1.2× 59 1.3× 20 1.2× 4 0.3× 11 1.0× 6 94

Countries citing papers authored by Thomas von Briel

Since Specialization
Citations

This map shows the geographic impact of Thomas von Briel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas von Briel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas von Briel more than expected).

Fields of papers citing papers by Thomas von Briel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas von Briel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas von Briel. The network helps show where Thomas von Briel may publish in the future.

Co-authorship network of co-authors of Thomas von Briel

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas von Briel. A scholar is included among the top collaborators of Thomas von Briel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas von Briel. Thomas von Briel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Schmid, Sabine, Sämi Schär, Oliver Gautschi, et al.. (2023). Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study. Lung Cancer. 187. 107427–107427. 9 indexed citations
5.
Mark, Michael, Beat Thürlimann, Karin Ribi, et al.. (2019). Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16). Journal of bone oncology. 21. 100273–100273. 11 indexed citations
6.
Lubeseder–Martellato, Clara, Ana Hidalgo‐Sastre, Irina Heid, et al.. (2016). Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic Lesions. EBioMedicine. 15. 90–99. 10 indexed citations
7.
Moos, Roger von, Dieter Koeberle, Richard Cathomas, et al.. (2012). Neoadjuvant radiotherapy (RT) combined with capecitabine (Cape) and sorafenib (Sor) in patients with locally advanced, K-ras-mutated rectal cancer (LARC): A phase I/II trial (SAKK 41/08).. Journal of Clinical Oncology. 30(15_suppl). 3595–3595. 1 indexed citations
8.
Grüner, Barbara M., Clara Lubeseder–Martellato, Thomas von Briel, et al.. (2011). Abstract PR11: Egfr is essential for Ras-driven pancreatic cancer development. Cancer Research. 71(18_Supplement). PR11–PR11. 1 indexed citations
9.
Payer, Michael & Thomas von Briel. (2007). Intradural pleural malignant mesothelioma. Acta Neurochirurgica. 149(10). 1053–1056. 14 indexed citations
10.
Cerny, T., Serge Leyvraz, Thomas von Briel, et al.. (1999). Saturable metabolism of continuous high-dose ifosfamide with Mesna and GM-CSF: A pharmacokinetic study in advanced sarcoma patients. Annals of Oncology. 10(9). 1087–1094. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026